Written question asked by Daisy Cooper (Liberal Democrat) on Wednesday, 14 December 2022, in the House of Commons. It was due for an answer on Monday, 19 December 2022. It was answered by Will Quince (Conservative) on Wednesday, 21 December 2022 on behalf of the Department of Health and Social Care.
Coronavirus: Immunosuppression
- Question
-
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 December 2022 to Question 97699 on Coronavirus: Immunosuppression, what the clinical guidance is to enable clinicians determine what constitutes exceptional circumstances in order for the antiviral Sotrovimab to be prescribed for immunosuppressed individuals.
- Answer
-
Recent guidance from the World Health Organization indicates that Sotrovimab does not neutralise the currently circulating COVID-19 variants and subvariants. NHS England has reviewed the clinical access policy for this drug which may still be considered as a treatment option where other available antiviral treatments are unsuitable.
Sotrovimab will now be prescribed by exception only where its use is supported following a multi-disciplinary team assessment. The revised clinical policy is available at the following link:
https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103218
Secondary information
- Type
- Written question
- Reference
- 110888
- Session
- 2022-23
- Related items
- Subjects
- Coronavirus Immunosuppression Sotrovimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2022-12-21 16:31:57 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/110888
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/110888
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/110888